EGFR CNGs were also reported in NSCLC and may play a role in response and survival to tyrosine kinase inhibitor therapy [6], [25], [26] while KRAS CNGs have not been investigated in depth in clinical tumors including NSCLCs. This evidence concerns the gene KRAS and non-small cell lung carcinoma.